开发肌萎缩侧索硬化症药物治疗方法的战略途径。
Strategic approaches to developing drug treatments for ALS.
作者信息
Vincent Andrea M, Sakowski Stacey A, Schuyler Adam, Feldman Eva L
机构信息
Department of Neurology, University of Michigan, Ann Arbor 48109, United States.
出版信息
Drug Discov Today. 2008 Jan;13(1-2):67-72. doi: 10.1016/j.drudis.2007.10.011. Epub 2007 Nov 26.
Abstract
Significant progress in understanding the cellular mechanisms of motor neuron degeneration in amyotrophic lateral sclerosis (ALS) has not been matched with the development of therapeutic strategies to prevent disease progression. The multiple potential causes and relative rarity of the disease are two significant factors that make drug development and assessment in clinical trials extremely difficult. We review recent progress in promoting therapeutics into clinical trials and highlight the value of moderate throughput screening for the acceleration and improvement of drug design.
摘要
在理解肌萎缩侧索硬化症（ALS）中运动神经元变性的细胞机制方面取得了重大进展，但在开发预防疾病进展的治疗策略方面却没有相应进展。该疾病的多种潜在病因以及相对罕见性是使药物开发和临床试验评估极为困难的两个重要因素。我们回顾了将治疗方法推进到临床试验的最新进展，并强调了适度高通量筛选对于加速和改进药物设计的价值。
相似文献
1
Strategic approaches to developing drug treatments for ALS.开发肌萎缩侧索硬化症药物治疗方法的战略途径。
Drug Discov Today. 2008 Jan;13(1-2):67-72. doi: 10.1016/j.drudis.2007.10.011. Epub 2007 Nov 26.
2
Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis.胰岛素样生长因子-I用于治疗肌萎缩侧索硬化症。
Amyotroph Lateral Scler. 2009 Apr;10(2):63-73. doi: 10.1080/17482960802160370.
3
[Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms].[肌萎缩侧索硬化症。当前的临床试验及潜在病理机制]
Nervenarzt. 2008 Jun;79(6):653-61. doi: 10.1007/s00115-007-2403-0.
4
Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.重组人胰岛素样生长因子I（rhIGF-I）用于治疗肌萎缩侧索硬化症/运动神经元病。
Cochrane Database Syst Rev. 2002(3):CD002064. doi: 10.1002/14651858.CD002064.
5
Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.肌萎缩侧索硬化症的实验性试验：对近期完成、正在进行以及计划开展的使用现有药物和新型药物的试验的综述
Expert Opin Investig Drugs. 2014 Nov;23(11):1541-51. doi: 10.1517/13543784.2014.933807. Epub 2014 Jun 26.
6
[Research in amyotrophic lateral sclerosis: what is new in 2009?].[肌萎缩侧索硬化症的研究：2009年有哪些新进展？]
Rev Neurol (Paris). 2010 Aug-Sep;166(8-9):683-98. doi: 10.1016/j.neurol.2010.03.006. Epub 2010 May 15.
7
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.力如太与依达拉奉：两种肌萎缩侧索硬化症药物的故事。
Med Res Rev. 2019 Mar;39(2):733-748. doi: 10.1002/med.21528. Epub 2018 Aug 12.
8
Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.重组人胰岛素样生长因子I（rhIGF-I）用于治疗肌萎缩侧索硬化症/运动神经元病。
Cochrane Database Syst Rev. 2007 Oct 17(4):CD002064. doi: 10.1002/14651858.CD002064.pub2.
9
Neuroprotective agents target molecular mechanisms of disease in ALS.神经保护剂针对 ALS 中的疾病分子机制。
Drug Discov Today. 2015 Jan;20(1):65-75. doi: 10.1016/j.drudis.2014.08.016. Epub 2014 Sep 6.
10
[Current Status of Drug Development for Amyotrophic Lateral Sclerosis].[肌萎缩侧索硬化症药物研发的现状]
Brain Nerve. 2024 Nov;76(11):1241-1249. doi: 10.11477/mf.1416202766.
引用本文的文献
1
RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice.RNA干扰介导的超氧化物歧化酶1沉默显著延长了肌萎缩侧索硬化症小鼠的生存期并改善了其功能结局。
bioRxiv. 2024 Jun 25:2024.06.20.599943. doi: 10.1101/2024.06.20.599943.
2
Neuronal Circuit Dysfunction in Amyotrophic Lateral Sclerosis.肌萎缩侧索硬化症中的神经元回路功能障碍。
Cells. 2024 May 7;13(10):792. doi: 10.3390/cells13100792.
3
Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and Beyond.铜 - 丙醛缩双甲硫基甲烷作为肌萎缩侧索硬化症的一种治疗方法：来自突变型超氧化物歧化酶1模型及其他方面的支持。
Life (Basel). 2020 Nov 4;10(11):271. doi: 10.3390/life10110271.
4
ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia.肌萎缩侧索硬化症的血液表达谱分析确定了新的生物标志物、患者亚组，以及嗜中性粒细胞增多和缺氧的证据。
J Transl Med. 2019 May 22;17(1):170. doi: 10.1186/s12967-019-1909-0.
5
Potential new complication in drug therapy development for amyotrophic lateral sclerosis.肌萎缩侧索硬化症药物治疗研发中潜在的新并发症。
Expert Rev Neurother. 2016 Dec;16(12):1397-1405. doi: 10.1080/14737175.2016.1207530. Epub 2016 Jul 15.
6
Emerging from the bottleneck: benefits of the comparative approach to modern neuroscience.走出瓶颈：比较方法对现代神经科学的益处。
Trends Neurosci. 2015 May;38(5):273-8. doi: 10.1016/j.tins.2015.02.008. Epub 2015 Mar 21.
7
Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.肌萎缩侧索硬化症患者静脉注射头孢曲松后的全身药代动力学及脑脊液摄取情况
J Clin Pharmacol. 2014 Oct;54(10):1180-7. doi: 10.1002/jcph.317. Epub 2014 May 16.
8
Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice.临床上可应用的抗心绞痛药物可抑制小鼠成肌细胞的成骨细胞转化和异位骨化。
J Bone Miner Metab. 2013 Jan;31(1):26-33. doi: 10.1007/s00774-012-0380-2. Epub 2012 Aug 24.
9
Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders.神经炎症的控制作为肌萎缩侧索硬化症和其他神经退行性疾病的治疗策略。
Exp Neurol. 2010 Mar;222(1):1-5. doi: 10.1016/j.expneurol.2009.12.018. Epub 2010 Jan 4.
10
Mouse models of Huntington disease: variations on a theme.亨廷顿病的小鼠模型：同一主题的变体
Dis Model Mech. 2009 Mar-Apr;2(3-4):123-9. doi: 10.1242/dmm.002451.
本文引用的文献
1
Current clinical trials in amyotrophic lateral sclerosis.目前针对肌萎缩侧索硬化症的临床试验。
Expert Opin Investig Drugs. 2007 Aug;16(8):1197-207. doi: 10.1517/13543784.16.8.1197.
2
Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish.突变型超氧化物歧化酶1的过表达导致斑马鱼运动轴突病。
Hum Mol Genet. 2007 Oct 1;16(19):2359-65. doi: 10.1093/hmg/ddm193. Epub 2007 Jul 17.
3
Molecular and cellular function of ALS2/alsin: implication of membrane dynamics in neuronal development and degeneration.ALS2/alsin的分子与细胞功能：膜动力学在神经元发育和退变中的作用
Neurochem Int. 2007 Jul-Sep;51(2-4):74-84. doi: 10.1016/j.neuint.2007.04.010. Epub 2007 May 4.
4
Quantitative objective markers for upper and lower motor neuron dysfunction in ALS.肌萎缩侧索硬化症中上、下运动神经元功能障碍的定量客观标志物。
Neurology. 2007 Apr 24;68(17):1402-10. doi: 10.1212/01.wnl.0000260065.57832.87.
5
Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation.重组人促红细胞生成素通过防止运动神经元死亡和炎症反应，抑制肌萎缩侧索硬化症G93A-SOD1小鼠模型的症状发作和进展。
Eur J Neurosci. 2007 Apr;25(7):1923-30. doi: 10.1111/j.1460-9568.2007.05471.x.
6
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons.表达与肌萎缩侧索硬化症相关的突变型超氧化物歧化酶1的星形胶质细胞释放对运动神经元有选择性毒性的因子。
Nat Neurosci. 2007 May;10(5):615-22. doi: 10.1038/nn1876. Epub 2007 Apr 15.
7
Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model.在基于胚胎干细胞的肌萎缩侧索硬化症模型中，神经胶质细胞对运动神经元的非细胞自主效应。
Nat Neurosci. 2007 May;10(5):608-14. doi: 10.1038/nn1885. Epub 2007 Apr 15.
8
Ethnic variation in the incidence of ALS: a systematic review.肌萎缩侧索硬化症发病率的种族差异：一项系统综述。
Neurology. 2007 Mar 27;68(13):1002-7. doi: 10.1212/01.wnl.0000258551.96893.6f.
9
Lost in translation: treatment trials in the SOD1 mouse and in human ALS.翻译过程中的迷失：SOD1基因小鼠和人类肌萎缩侧索硬化症的治疗试验
Neurobiol Dis. 2007 Apr;26(1):1-13. doi: 10.1016/j.nbd.2006.12.015. Epub 2007 Jan 3.
10
Molecular Diagnosis and Biomarker Identification on SELDI proteomics data by ADTBoost method.基于ADTBoost方法的表面增强激光解吸电离飞行时间质谱蛋白质组学数据的分子诊断与生物标志物识别
Conf Proc IEEE Eng Med Biol Soc. 2005;2005:4771-4. doi: 10.1109/IEMBS.2005.1615538.
Zotero 插件